Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NKTR

Nektar Therapeutics

Healthcare | Biotechnology

No licensed closing price on file for NKTR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Nektar Therapeutics (NASDAQ: NKTR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:50 UTC.

What Nektar Therapeutics does

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing immunomodulatory drugs to treat autoimmune diseases and cancer by selectively modifying immune responses. The company's approach focuses on restoring immune balance in autoimmune conditions and activating tumor-fighting immune mechanisms in oncology. Rezpegaldesleukin, its lead autoimmune candidate, works by stimulating regulatory T cells and is being studied in atopic dermatitis, alopecia areata, and type 1 diabetes through multiple clinical trials.

Summarized from Nektar Therapeutics’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-182.65%

Revenue, margins & earnings

FY2021: net loss $524M on revenue $102M$102MFY2021FY2022: net loss $368M on revenue $92M$92MFY2022FY2023: net loss $276M on revenue $90M$90MFY2023FY2024: net loss $119M on revenue $98M$98MFY2024FY2025: net loss $164M on revenue $55M$55MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-25
  • 2026-09-25DirectorStock OptionAward4,000—
  • 2026-09-25DirectorAward2,000—
  • 2026-09-25DirectorAward2,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Nektar Therapeutics do?

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing immunomodulatory drugs to treat autoimmune diseases and cancer by selectively modifying immune responses.

When did NKTR last file with the SEC?

Nektar Therapeutics's most recent SEC filing on record is a 8-K filed 2026-06-05. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:50 UTC. This page is also available as JSON at /api/data?ticker=NKTR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NKTR and 5,000+ tickers.

Create a free account — keep NKTR
For your agent
GET /api/data?ticker=NKTR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt